Compounds as NLRP3 inflammasome inhibitors and compositions and uses thereof

Patent metadata

Field	Value
Publication number	US-12221406-B2
Application number	US-202017627214-A
Country	US
Kind code	B2
Filing date	Jul 15, 2020
Priority date	Jul 16, 2019
Publication date	Feb 11, 2025
Grant date	Feb 11, 2025

Abstract

Scaffold compounds are used to design small molecule compounds and structure-activity relationship studies identify inhibitors of inflammation. Methods include pharmaceutical compositions of the small molecule compounds to inhibit, prevent and treat diseases and conditions associated with inflammation, including multiple sclerosis, Alzheimer's disease, acute myocardial infarction, traumatic brain injury and autoinflammatory diseases.

First claim

I claim:

1. A compound having the chemical structure of

and pharmaceutically acceptable salts, solvates, or hydrates thereof.

Assignees

• Univ Virginia Commonwealth

Inventors

• Zhang Shijun

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D409/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D333/24

  Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• C07D317/62

  with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring · CPC title

• C07D307/64

  Sulfur atoms · CPC title